文献リスト

1）Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49: 1335-74

2）Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54: 1433-44

3）Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461: 399-401

4）Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41: 1105-9

5）Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41: 1100-4

6）Thompson AJ, Fellay J, Patel K, et al. Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia and Decrease the Need for Ribavirin Dose Reduction. Gastroenterology. 2010; 139(4): 1181-9

7）Ochi H, Maekawa T, Abe H, et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy-a genome-wide study of Japanese HCV virus patients. Gastroenterology. 2010; 139(4): 1190-7

8）Mangia A, Thompson AJ, Santoro R, et al. Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology 2011; 54: 772-80

9）Sarrazin C, Schwendy S, Moller B, et al. Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. Gastroenterology 2011; 141: 1656-64

10）McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009; 360: 1827-38

11）Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009; 360: 1839-50

12）McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010; 362: 1292-303

13）Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364: 2405-16

14）Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011; 365: 1014-24

15）Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011; 364: 2417-28

16）Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012; 56: 78-84

17）Hayashi N, Okanoue T, Tsubouchi H, et al. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2012; 19: 134-42

18）Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010; 52: 421-9

19）Suzuki F, Suzuki Y, Akuta N, et al. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology. 2011; 53: 415-21

20）Foster GR, Hezode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology. 2011; 141: 881-9

21）Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010; 376(9742): 705-16

22）Poordad F, McCone J, Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364(13): 1195-206

23）Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364: 1207-17

24）Manns MP, Gane E, Rodriguez-Torres M, et al. Vaniprevir with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C - a randomized phase 2 study. Hepa-tology. in press

25）Reesink HW, Fanning GC, Farha KA, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology. 2010; 138(3): 913-21

26）Manns M, Reesink H, Berg T, et al. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther. 2011; 16: 1021-33

27）Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol. 2012; 56: 1247-53

28）Fried M, Buti M, Dore GJ, et al. TMC435 in combination with peginterferon and ribavirin in treatment-naïve HCV genotype 1 patients: Final analysis of the PILLAR phase 2b study. Hepatology. 2011; 54(Suppl): 1429A

29）Zeuzem S, Berg T, Gane E, et al. TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon/ribavirin treatment: Final SVR24 results of the ASPIRE trial. J Hepatol. 2012; 56(Suppl.2): S1

30）Forestier N, Larrey D, Guyader D, et al. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: A phase 1b multiple ascending dose study. J Hepatol. 2011; 54(6): 1130-6

31）Terrault N, Cooper C, Balart LA, et al. High sustained virologic response (SVR24) rates with response-guided danoprevir (DNV; RG7227) plus pegIFN α-2a (40Kd) and ribavirin in treatment-naïve HCV genotype 1 patients: Results from the ATLAS study. Hepatology. 2011; 54(Suppl): 398A

32）Manns MP, Bourliere M, Benhamu Y, et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol. 2011; 54: 1114-22

33）Sulkowski MS, Ceasu E, Asselah T, et al. SILEN-C1: Sustained virologic response and safety of BI201335 combined with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype 1 HCV infection. J Hepatol. 2011; 54(Suppl.1): S27

34）Sulkowski MS, Bourliere M, Bronowicki JP, et al. SILEN-C2: Sustained virologic response and safety of BI201335 combined with peginterferon alfa-2a and ribavirin (P/R) in chronic HCV genotype-1 patients with non-response to P/R. J Hepatol. 2011; 54(Suppl.1): S30

35）Guedj J, Dahari H, Shudo E, et al. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology. 2012; 55: 1030-7

36）Pockros P, Jensen D, Tsai N, et al. First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon/ribavirin in treatment-naïve HCV G1/4 patients: Interim analysis from the JUMP-C trial. J Hepatol. 2011; 54(Suppl.1): S538

37）Lawitz E, Lalezari JP, Hassanein T, et al. Once-daily PSI-7977 plus PEG/RBV in treatment-naïve patients with HCV GT1: Robust end of treatment response rates are sustained post-treatment. Hepatology. 2011; 54(Suppl): 472A

38）Gane EJ, Atedman CA, Hyland RH, et al. Once- daily PSI-7977 plus RBV: pegylated interferon-alfa not required for complete rapid viral response on treatmen-naïve patients with HCV GT2 or GT3. Hepatology. 2011; 54(Suppl): 377A

39）Kowdley KV, Lawitz E, Crespo I, et al. ATOMIC: 97% RVR for PSI-7977+PEG/RBV × 12 week regimen in HCV GT1: an end to response-guided therapy? J Hepatol. 2012; 56(Suppl.2): S1

40）Wagner F, Thompson R, Kantaridis C, et al. Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients. Hepatology. 2011; 54: 50-9

41）Nettles RE, Gao M, Bifano M, et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology. 2011; 54: 1956-65

42）Pol S, Ghalib RH, Rustgi VK, et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis. In press

43）Hezode C, Hirschfield GM, Ghesquiere W, et al. BMS-790052, a NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin treatment-naïve HCV-genotype 1 or 4 patients: phase 2B AI444010 study interim week 12 results. Hepatology. 2011; 54(Suppl): 474A

44）Izumi N, Asahina Y, Yokosuka O, et al. Combination therapy of treatment-naïve and nonresponder patients with HCV genotype 1 infection with BMS-790052, an NS5A replication complex inhibitor, in combination with peginterferon alfa-2a and ribavirin. Hepatology. 2011; 54(Suppl): 1439A

45）Suzuki F, Chayama K, Kawakami Y, et al. BMS-790052, an NS5A replication complex inhibitor, in combination with peginterferon alpha-2b and ribavirin in Japanese treatment-naïve and non-responder patients with chronic HCV genotype 1 infection. Hepatology. 2011; 54(Suppl): 1441A

46）Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2010; 376(9751): 1467-75

47）Di Bisceglie AM, Nelson D.R, Gane E, et al. VX-222 with TVR alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: ZENITH study interim results. J Hepatol. 2011; 54 (Suppl.1): S540

48）Zeuzem S, Asselah T, Angus P, et al. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology. 2011; 141: 2047-55

49）Zeuzem S, Soriano V, Asselah T, et al. SVR4 and SVR12 with an interferon-free regimen of BI201335 and BI207127, +/- ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: interim results of SOUND-C2. J Hepatol. 2012; 56(Suppl.2): S45

50）Zeuzem S, Buggisch P, Agarwal K, et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology. 2012; 55: 749-58

51）Nelson DR, Lawitz E, Bain V, et al. High SVR12 with 16 weeks of tegobuvir and GS-9256 with peginterferon-alfa 2a and ribavirin in treatment-naive genotype 1 HCV patients. J Hepatol. 2012; 56(Suppl.2): S6

52）Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012; 366: 216-24

53）Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 2012; 55: 742-8

54）Suzuki F, Ikeda K, Toyota J, et al. Dual oral therapy with the NS5A inhibitor daclatasvir (BMS-790052) and NS3 protease inhibitor asunaprevir (BMS-650032) in HCV genotype 1b-infected null responders or ineligible/intolerant to peginterferon/ribavirin. J Hepatol. 2012; 56(Suppl.2): S7

55）Muir AJ, Shiffman ML, Zaman A, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepa-tology. 2010; 52(3): 822-32

56）Zeuzem S, Arora S, Bacon B, et al. Peginterferon lamda-1A (LAMBDA) compared to peginterferon alfa-2a (ALFA) in treatment-naïve patients with HCV genotypes (G) 2 or 3: First SVR24 results from EMERGE phase2b. J Hepatol. 2012; 56 (Suppl.2): S5

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp